Thus, underlying differences in the functional immune state of the TME—coupled with alterations in CD4+ T cell effector activity versus suppression and tumor cell-specific CXCL13 expression—appear to be associated with distinct spatial cellular patterns that predict the efficacy of PD-1 blockade in CTCL. The gene discussed is CD4; the disease is neoplasm.